Nutriband Inc. (NASDAQ: NTRB) has achieved a significant milestone by being added to four Russell indexes as part of the 2025 Russell indexes reconstitution. The company is now part of the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes. This inclusion is a testament to the market's recognition of Nutriband's growth and the potential of its AVERSA pipeline, particularly AVERSA Fentanyl, which is projected to have peak annual U.S. sales between $80 million and $200 million.
The Russell indexes, maintained by FTSE Russell, are a benchmark for approximately $10.6 trillion in assets and are widely utilized by investment managers and institutional investors. Nutriband's CEO, Gareth Sheridan, emphasized that this inclusion reflects the momentum behind the company's innovative AVERSA technology. AVERSA technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, marking a significant advancement in transdermal pharmaceutical products.
Nutriband's lead product under development, an abuse-deterrent fentanyl patch incorporating AVERSA technology, represents a critical step forward in addressing the opioid crisis. The technology's versatility allows it to be incorporated into any transdermal patch, offering broad applications in the pharmaceutical industry. For more detailed information, visit https://ibn.fm/wa35e.
This development not only underscores Nutriband's innovative approach to pharmaceutical development but also positions the company for significant growth in the coming years. The inclusion in the Russell indexes is likely to enhance Nutriband's visibility among investors and potentially lead to increased investment in the company's groundbreaking technologies.
